TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: increase in erythroid gene markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximal ANC (Absolute Neutrophil Count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Global perceived recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk of cardiovascular hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Risk of heart failure hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Risk of non-heart failure related cardiovascular hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: 7-day avoidance of cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10,000-m running performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mRNA expressions of PBMNC T‐bet and STAT4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: levels of IFN‐gamma and IL‐12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of superficial incisional SSI
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Pressure (BP) Measurement Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: primary CV endpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of NPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in QOL-AD
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: rates of hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Conversion to PSA level >= 4 ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean seat time per shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: back cycles per shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: seat cycles per shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: caster distance rolled per shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: happiness of patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: bother from pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean medication scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence rate (≥ 95%)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: gain in body-weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of RAS-associated pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Major uterine wound extensions
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in body fat percentage (BF%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 25(OH)D2 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 1,25(OH)2D concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FGF23 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity of Post-Thrombotic Syndrome (PTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC1‐12 t‐PA antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AUC1‐12 PAI‐1 antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PGA (Physician's Global Assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Understanding of surgical consent
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Elicited skin pressures (mN/mm(2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reliability between observers (Intraclass correlation coefficients)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antacid consumption reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major life problems experienced
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Reduction in phacoemulsification time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in overall energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accuracy of capsulorhexis diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: LA maximum volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LA active emptying volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Viral failure in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dermal anesthesia effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Peak myocardial velocity gradient in the anteroseptum during systole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak myocardial velocity gradient in the posterior wall during systole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak myocardial velocity gradient in the posterior wall during diastole
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participants free of PTSD
Endpoint domain: Mortality/survival
Primary endpoint: Improvement on child-report questionnaire measures of PTSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician-rated functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of home treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: improvement in acupuncture treatment outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to positive culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous breathing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients receiving Papanicolaou smear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients receiving fecal occult blood slide test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients receiving clinical breast examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sequelae after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of gel versus suppository
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median survival of patients
Endpoint domain: Mortality/survival
Primary endpoint: overall sexual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hospital-acquired pressure ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of nurses needed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: cumulative survival of dentin caries lesion-free occlusal pits and fissures
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in HE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events related to circumcision
Endpoint domain: Adverse events/effects
Primary endpoint: Resumption of normal general activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevention of antibiotic associated diarrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cumulative radiation exposure
Endpoint domain: Adverse events/effects
Primary endpoint: corticomotoneuronal excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Skin hardening (morphea-like skin changes)
Endpoint domain: Adverse events/effects
Primary endpoint: pruritus duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patients' global satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Progression-free survival with PSA level less than 1.5 ng/mL
Endpoint domain: Mortality/survival
Primary endpoint: Visual field loss prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Serotonin level increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of hearing loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Auditory outcomes
Primary endpoint: Frequency of opioid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiovascular/renal rehospitalization or death at 60 days
Endpoint domain: Mortality/survival
Primary endpoint: effective orifice area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pressure difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unwanted effects
Endpoint domain: Adverse events/effects
Primary endpoint: Preference for route of administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of contrast induced nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: peak increase in serum creatinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: peak decrease in estimated glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ADAS-cog scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regional cerebral blood flow measure improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GMCs for serotypes 4, 9V, 18C and 19F
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VT antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody levels maintained to age 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cholesterol concentrations in LDL particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean loss of handgrip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time required for ulcer healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completely healed ulcers percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failed rate
Endpoint domain: Adverse events/effects
Primary endpoint: Suppression of Ki67
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in MAC of sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in MAC(awake)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived recovery-stress state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: triazolam clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elimination half-life of triazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sedation and performance impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Insulin Resistance (IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the secretory curve (AUC) of GH secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incidence of postoperative infections
Endpoint domain: Adverse events/effects
Primary endpoint: Body temperature on postoperative days 1-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRP level on postoperative days 1-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate and severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-infinity) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean plasma elimination half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain-free postoperative time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean number of minutes before requesting pain rescue medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average pain medication consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained decrease in serum p24 antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean CD4 lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: waiting time
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: SVR24 achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin sensitivity index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: death or inability to walk unaided at 48 weeks
Endpoint domain: Mortality/survival
Primary endpoint: hospital admissions due to cardiac disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: level of physical performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Edoxaban exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sustained vision improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delirium severity at 8-week follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stenotic progression (MOD and MSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: feelings of hunger and satiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of BMI ≥25 kg/m2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Need for additional treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 24-hour systolic BP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-hour diastolic BP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of prediabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Childhood mortality
Endpoint domain: Mortality/survival
Primary endpoint: Average postoperative hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Compliance with PPD test screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Decreased DCP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Decreased AFP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Progression to Alzheimer's Disease (AD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hippocampal volumetric loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in precision in MIC training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GOALS-Scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MISTELS score trend improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants nonadherent to diagnostic follow-up
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Timing of initial follow-up
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Baseline knowledge regarding infant hearing loss diagnosis recommendations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maternal postpartum hemorrhage (PPH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of valid blood gas samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor regressions including one objective partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: postprandial incremental areas under the curve (IAUCs) of triglyceride-rich lipoproteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral vasospasm prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Need for amniotomy and oxytocin for induction of labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of significant air leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association between 9-repeat allele of DAT1 and BPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: National Institutes of Health Stroke Scale (NIHSS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant depressive or mood-disturbance symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to intervention (self-sample or cytology attendance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance for cytology screening after positive hrHPV result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target AD level achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Normalization of AD circadian profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decreased frequency of target organ affection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Declines in total agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Declines in physical nonaggressive agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Declines in verbal agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increases in pleasure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increases in interest
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean change in baseline weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Systemic pressor response to norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma concentrations of tumor necrosis factor-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ulnar motor response recorded
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Radial motor response recorded
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GSV occlusion or absence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: AVVSS improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Perioperative pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean M-PASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Visual analog scale score for pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: calorie intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return to routine activities
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Occlusion of the GSV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement of the quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical child abuse risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes